GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » Valuation Rank

Median Technologies (XPAR:ALMDT) Valuation Rank


View and export this data going back to 2011. Start your Free Trial

What is Median Technologies Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Median Technologies Valuation Rank Related Terms

Thank you for viewing the detailed overview of Median Technologies's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Median Technologies (XPAR:ALMDT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » Valuation Rank
Comparable Companies
XPAR:ALBIO XPAR:ALCAR XPAR:AFME XPAR:ALNOV XPAR:ALMKT XPAR:ALTHE XPAR:ALTER XPAR:ALBLU XPAR:ALDMS XPAR:ALEMG ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
4ZG:Germany
Address
1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560
Website
https://www.mediantechnologies.com
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.